Clarity Pharmaceuticals
Clarity Pharmaceuticals, a Sydney radiopharmaceutical company, pairs copper isotopes with SAR-bisPSMA, a molecule that binds PSMA on prostate cancer cells: copper-64 for PET imaging, in the phase 3 AMPLIFY and CLARIFY trials, and copper-67 for therapy in the SECuRE trial. The copper-67 therapy is still at the dose-finding stage.
Overview
Co-PSMA head-to-head data (EAU 2026) showed Cu-64 SAR-bisPSMA more than doubled lesion and patient detection versus Ga-68 PSMA-11; FDA Fast Track in biochemical recurrence; commercial manufacturing agreement with Nucleus RadioPharma (April 2026). SECuRE therapy trial: 7 of 19 patients at 8 GBq 67Cu reached complete response or undetectable disease (July 2026).
Scorecard
All companies- phase 3 +3
- targets +2
- modalities +2
An experimental PET tracer for prostate cancer that binds the same target as approved PSMA scans (PSMA) but, because its radioactive tag lasts longer, can be re-imaged a day later to catch small deposits the first picture missed. It is not yet approved for sale.
Similar pages
not linked directly; found by shared links- IdeaA single-molecule copper-64/copper-67 pair instead of switching ligands between scan and treatment
Shares 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE), Copper-67, Copper-64, PSMA.
- PersonThomas A. Hope
Shares PSMA, PSMA PET, Gallium-68, Radioligand therapy (beta emitters).
- PersonJohannes Czernin
Shares PSMA, PSMA PET, Gallium-68, Radioligand therapy (beta emitters).
- PersonPeter Bartenstein
Shares PSMA, PSMA PET, Gallium-68, Radioligand therapy (beta emitters).
- PersonJeremie Calais
Shares PSMA, PSMA PET, Gallium-68, Radioligand therapy (beta emitters).
- AgentLocametz (kit for Ga-68 gozetotide)
Shares Theranostics, PSMA, PSMA PET, Gallium-68.
- PersonRahul Aggarwal
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
- InstitutionIRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST)
Shares Theranostics, PSMA, PSMA PET, Radioligand therapy (beta emitters).